KAPA (Kairos Pharma) Debt-to-Equity : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Debt-to-Equity?

Kairos Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Kairos Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Kairos Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $4.78 Mil. Kairos Pharma's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kairos Pharma's Debt-to-Equity or its related term are showing as below:

KAPA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.49 Med: -0.32 Max: -0.15
Current: 0.03

During the past 5 years, the highest Debt-to-Equity Ratio of Kairos Pharma was -0.15. The lowest was -0.49. And the median was -0.32.

KAPA's Debt-to-Equity is ranked better than
81.22% of 1017 companies
in the Biotechnology industry
Industry Median: 0.14 vs KAPA: 0.03

Kairos Pharma Debt-to-Equity Historical Data

The historical data trend for Kairos Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Debt-to-Equity Chart

Kairos Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

-0.15

-0.33

-0.49

-0.31

Kairos Pharma Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial									-0.31	-	-	0.04	-

Competitive Comparison of Kairos Pharma's Debt-to-Equity

For the Biotechnology subindustry, Kairos Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Kairos Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kairos Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.776
	=	0.00

Kairos Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.776
	=	0.00

Kairos Pharma (AMEX:KAPA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kairos Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064

Website

https://kairospharma.com

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.